Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Spero Therapeutics's Enterprise Value is $19.88 Mil.
Spero Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $7.24 Mil. Therefore, Spero Therapeutics's EV-to-OCF for today is 2.75.
The historical rank and industry rank for Spero Therapeutics's EV-to-OCF or its related term are showing as below:
SPRO'
s EV-to-OCF Range Over the Past 10 Years
Min: -11.05 Med: -1.69 Max: 15.13
Current: 2.75
During the past 11 years, the highest EV-to-OCF of Spero Therapeutics was 15.13. The lowest was -11.05. And the median was -1.69.
SPRO's EV-to-OCF is ranked worse than 79.22% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs SPRO: 2.75
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Spero Therapeutics's PE Ratio (TTM) for today is calculated as:
Spero Therapeutics's share price for today is $1.27.
Spero Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Spero Therapeutics EV-to-OCF Related Terms
Spero Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spero Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's EV-to-OCF falls into.
Spero Therapeutics's current Enterprise Value is $19.88 Mil.
Spero Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (SPRO) has a EV-to-OCF of 2.75 as of Aug. 10, 2026. According to the industry distribution chart, Spero Therapeutics ranks #1113 out of 1405 companies in the Biotechnology industry, placing it in the top 79.2%.
Is Spero Therapeutics' EV-to-OCF too high?
Spero Therapeutics' current EV-to-OCF is 2.75. Based on the distribution chart, Spero Therapeutics ranks #1113 out of 1405 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spero Therapeutics has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' EV-to-OCF compare to ACRV and BSEM?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #1113 out of 1405 companies for EV-to-OCF. This places Spero Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Spero Therapeutics's current EV-to-OCF is 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $1.27 — trading 21% above its estimated fair value. The current EV-to-OCF is 2.75. Spero Therapeutics' overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current EV-to-OCF is 2.75 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of $1.27 is trading 21% above its estimated GF Value™ of $1.05.
GuruFocus considers Spero Therapeutics to be Modestly Overvalued.
Key valuation signals for SPRO:
EV-to-OCF: 2.75
GF Value™: $1.05 vs. price of $1.27 (21% above fair value)
No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
69GF Score
Get the complete analysis for SPRO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
